MA39406A1 - Promédicament de la 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline - Google Patents
Promédicament de la 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-prolineInfo
- Publication number
- MA39406A1 MA39406A1 MA39406A MA39406A MA39406A1 MA 39406 A1 MA39406 A1 MA 39406A1 MA 39406 A MA39406 A MA 39406A MA 39406 A MA39406 A MA 39406A MA 39406 A1 MA39406 A1 MA 39406A1
- Authority
- MA
- Morocco
- Prior art keywords
- bis
- hexanediyl
- dioxo
- prodrug
- proline
- Prior art date
Links
- HZLAWYIBLZNRFZ-VXGBXAGGSA-N cphpc Chemical compound OC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1[C@@H](C(O)=O)CCC1 HZLAWYIBLZNRFZ-VXGBXAGGSA-N 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010002022 amyloidosis Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- KSKLDMGKWDUQCT-DNQXCXABSA-N oxan-4-yloxycarbonyloxymethyl (2R)-1-[6-[(2R)-2-(oxan-4-yloxycarbonyloxymethoxycarbonyl)pyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylate Chemical compound C(CCCCC(=O)N1[C@H](CCC1)C(=O)OCOC(=O)OC1CCOCC1)(=O)N1[C@H](CCC1)C(=O)OCOC(=O)OC1CCOCC1 KSKLDMGKWDUQCT-DNQXCXABSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne le composé qu'est le (2r,2'r)-bis(((((tétrahydro-2h-pyran-4-yl)oxy)carbonyl)oxy)méthyl)1,1'-adipoylbis(pyrrolidine-2-carboxylate), des compositions pharmaceutiques en contenant et leur utilisation en vue du traitement de maladies ou de troubles dans lesquels la déplétion en composant p de l'amyloïde sérique (sap) serait bénéfique, cela comprenant l'amylose, la maladie d'alzheimer, le diabète de type 2 et l'arthrose.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1407506.3A GB201407506D0 (en) | 2014-04-29 | 2014-04-29 | Novel compound |
| PCT/EP2015/058998 WO2015165833A1 (fr) | 2014-04-29 | 2015-04-27 | Promédicament de la 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA39406A1 true MA39406A1 (fr) | 2017-07-31 |
| MA39406B1 MA39406B1 (fr) | 2018-04-30 |
Family
ID=50972033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39406A MA39406B1 (fr) | 2014-04-29 | 2015-04-27 | Promédicament de la 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US9701668B2 (fr) |
| EP (1) | EP3137457B1 (fr) |
| JP (1) | JP6445046B2 (fr) |
| KR (1) | KR20160145617A (fr) |
| CN (1) | CN106459016B (fr) |
| AR (1) | AR100204A1 (fr) |
| AU (1) | AU2015252184B2 (fr) |
| BR (1) | BR112016025129A2 (fr) |
| CA (1) | CA2947060C (fr) |
| CL (1) | CL2016002721A1 (fr) |
| CR (1) | CR20160508A (fr) |
| DO (1) | DOP2016000292A (fr) |
| EA (1) | EA032129B1 (fr) |
| ES (1) | ES2731253T3 (fr) |
| GB (1) | GB201407506D0 (fr) |
| IL (2) | IL248249A0 (fr) |
| MA (1) | MA39406B1 (fr) |
| MX (1) | MX2016014246A (fr) |
| MY (1) | MY191088A (fr) |
| PE (1) | PE20161558A1 (fr) |
| PH (1) | PH12016502006B1 (fr) |
| SG (1) | SG11201608371RA (fr) |
| TW (1) | TWI676624B (fr) |
| UA (1) | UA119871C2 (fr) |
| UY (1) | UY36098A (fr) |
| WO (1) | WO2015165833A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9737505B2 (en) | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
| GB201518950D0 (en) * | 2015-10-27 | 2015-12-09 | Glaxosmithkline Ip Dev Ltd | Compound |
| GB202213162D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Prodrugs |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2182203T3 (es) | 1997-10-31 | 2003-03-01 | Hoffmann La Roche | Derivados de d-prolina. |
| US6903129B2 (en) * | 2001-12-14 | 2005-06-07 | Hoffman-La Roche Inc. | D-proline prodrugs |
| JP2006526612A (ja) | 2003-06-05 | 2006-11-24 | ファイザー・プロダクツ・インク | ベータ−ラクタマーゼ阻害剤・プロドラッグ |
| GB0313386D0 (en) | 2003-06-10 | 2003-07-16 | Univ London | Treatment of disease |
| KR20080004571A (ko) | 2005-04-12 | 2008-01-09 | 메이지 세이카 가부시키가이샤 | 2-티오에테닐 카바페넴 유도체 |
| GB0712503D0 (en) | 2007-06-27 | 2007-08-08 | Therapeutics Pentraxin Ltd | Use |
| UA108227C2 (xx) | 2010-03-03 | 2015-04-10 | Антигензв'язуючий білок | |
| US9737505B2 (en) | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
-
2014
- 2014-04-29 GB GBGB1407506.3A patent/GB201407506D0/en not_active Ceased
-
2015
- 2015-04-27 EA EA201692185A patent/EA032129B1/ru not_active IP Right Cessation
- 2015-04-27 SG SG11201608371RA patent/SG11201608371RA/en unknown
- 2015-04-27 CN CN201580023347.0A patent/CN106459016B/zh not_active Expired - Fee Related
- 2015-04-27 TW TW104113338A patent/TWI676624B/zh not_active IP Right Cessation
- 2015-04-27 JP JP2016565212A patent/JP6445046B2/ja not_active Expired - Fee Related
- 2015-04-27 UY UY0001036098A patent/UY36098A/es not_active Application Discontinuation
- 2015-04-27 PE PE2016001934A patent/PE20161558A1/es unknown
- 2015-04-27 AU AU2015252184A patent/AU2015252184B2/en not_active Ceased
- 2015-04-27 US US14/787,608 patent/US9701668B2/en not_active Expired - Fee Related
- 2015-04-27 UA UAA201612105A patent/UA119871C2/uk unknown
- 2015-04-27 AR ARP150101262A patent/AR100204A1/es active IP Right Grant
- 2015-04-27 ES ES15720312T patent/ES2731253T3/es active Active
- 2015-04-27 KR KR1020167029703A patent/KR20160145617A/ko not_active Ceased
- 2015-04-27 MY MYPI2016703952A patent/MY191088A/en unknown
- 2015-04-27 CA CA2947060A patent/CA2947060C/fr active Active
- 2015-04-27 CR CR20160508A patent/CR20160508A/es unknown
- 2015-04-27 WO PCT/EP2015/058998 patent/WO2015165833A1/fr not_active Ceased
- 2015-04-27 MA MA39406A patent/MA39406B1/fr unknown
- 2015-04-27 BR BR112016025129A patent/BR112016025129A2/pt not_active Application Discontinuation
- 2015-04-27 MX MX2016014246A patent/MX2016014246A/es active IP Right Grant
- 2015-04-27 EP EP15720312.6A patent/EP3137457B1/fr active Active
-
2016
- 2016-10-09 IL IL248249A patent/IL248249A0/en active IP Right Grant
- 2016-10-10 PH PH12016502006A patent/PH12016502006B1/en unknown
- 2016-10-26 CL CL2016002721A patent/CL2016002721A1/es unknown
- 2016-10-28 DO DO2016000292A patent/DOP2016000292A/es unknown
-
2017
- 2017-06-01 US US15/610,984 patent/US9873686B2/en not_active Expired - Fee Related
- 2017-12-11 US US15/837,297 patent/US10597385B2/en active Active
-
2020
- 2020-12-01 IL IL279120A patent/IL279120A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2019000099A1 (fr) | Anticorps anti-lag-3 et compositions | |
| BR112015016315A2 (pt) | fluoro-[1,3]oxazinas como inibidores de bace1 | |
| EA201300213A1 (ru) | Применение ингибиторов dpp iv | |
| MA44948A1 (fr) | Inhibiteurs de bace 1 | |
| MA40283A (fr) | Aptamères spécifiques du récepteur tlr-4 et leurs utilisations | |
| MA43113B1 (fr) | Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci | |
| MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
| MA39146A1 (fr) | Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma | |
| EA202091446A1 (ru) | Способы лечения хронических воспалительных заболеваний | |
| WO2018071741A8 (fr) | Sulfoxyalkyle organonitro, composés apparentés et compositions pharmaceutiques destinées à être utilisées en médecine | |
| MA39447A1 (fr) | (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
| MA39406B1 (fr) | Promédicament de la 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline | |
| EP3881849A4 (fr) | Composition comprenant un aptamère en tant que principe actif pour le traitement et la prévention d'une maladie dégénérative du cerveau | |
| MA46778B1 (fr) | Composition intranasale comprenant de la bétahistine | |
| EA201990550A1 (ru) | Офтальмологический препарат, включающий азоловое соединение | |
| MA39448B1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| BR112017015474A2 (pt) | inibidores de bace1 | |
| BR112016007430A2 (pt) | 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas | |
| EP2873419A4 (fr) | Composition pharmaceutique comprenant de l'azathioprine en tant que principe actif pour la prévention ou le traitement de tumeurs du cerveau ou de glioblastomes résistants à témodal | |
| MA46415A (fr) | Complexe et compositions pour le traitement de maladies ophtalmiques et dermatologiques | |
| EP3295947A4 (fr) | Composition pharmaceutique pour la prévention et le traitement de la maladie pulmonaire obstructive chronique contenant, comme principe actif, un extrait, une fraction ou une fraction active deflos magnoliae | |
| MA38487A1 (fr) | Agents séquestrants de précurseurs de produits terminaux de glycation avancée (age) | |
| EP3831397A4 (fr) | Composition pharmaceutique comprenant comme principe actif de la proanthocyanidine pour la prévention ou le traitement du carcinome épidermoïde | |
| BR112018008582A2 (pt) | derivados de d-prolina como agentes de eliminação de sap | |
| EP3777852C0 (fr) | Composition pharmaceutique comprenant un composé dérivé de la 1,2-naphtoquinone pour la prévention ou le traitement de cancers solides ou de cancers du sang |